- Home
- CHNR vs CYCN Comparison
CHNR vs CYCN Comparison
Compare CHNR & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CHNR | CYCN |
|---|---|---|
| Founded | N/A | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3M | 5.7M |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | CHNR | CYCN |
|---|---|---|
| Price | $4.10 | $6.31 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 768.7K | ★ 7.5M |
| Earning Date | 05-14-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.45 | $1.03 |
| 52 Week High | $57.47 | $8.48 |
Technical Indicators
Market Signals| Indicator | CHNR | CYCN |
|---|---|---|
| Relative Strength Index (RSI) | 50.43 | 93.33 |
| Support Level | $3.31 | $2.30 |
| Resistance Level | $4.25 | N/A |
| Average True Range (ATR) | 0.55 | 0.47 |
| MACD | -0.01 | 0.46 |
| Stochastic Oscillator | 32.82 | 67.78 |
Price Performance
Historical ComparisonAbout CHNR China Natural Resources Inc.
China Natural Resources Inc is engaged in exploration for lead, silver, and other metals in the Inner Mongolia Autonomous Region of the PRC and exploration of attractive opportunities in other sectors. The company has a single operating segment: exploration and mining.
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.